Article: Rhone-Poulenc Rorer Announces Major Expansion of Manufacturing in Singapore

Plant to Manufacture World's Best-Selling Low Molecular Weight Heparin

/Editors: This press release was issued earlier in Australia./

COLLEGEVILLE, Pa., and SINGAPORE, May 12 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) announced today that it will invest $50 million USD ($75 million Singapore dollars) to build a new chemical manufacturing plant for the production of enoxaparin sodium, the active ingredient in Lovenox(R)/Clexane(R) Injection.

Lovenox/Clexane is a low-molecular-weight heparin used in the prevention of deep-vein thrombosis following hip and knee surgery and is the world's leading low-molecular-weight heparin ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!